Scarica l'app Stockscreener
43.60
0.07%
-0.03
Dopo l'orario di chiusura:
43.61
0.010
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Sanofi Adr Borsa (SNY) Ultime notizie
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 - GlobeNewswire Inc.
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz
Antibiotics Market - GlobeNewswire Inc.
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz
How Do Investors Really Feel About Sanofi SA? - Sahm
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz
Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz
Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz
Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease - Sahm
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz
European ADRs Slip, But Still End The Week Higher - Finimize
Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa
SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com
Earnings Preview: Sanofi - Sahm
Berenberg Bank Remains a Buy on Sanofi (SNY) - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):